Tilray Brands, Inc. Revenue from Contract with Customer, Including Assessed Tax
Tilray Brands, Inc. (TLRY) reported Revenue from Contract with Customer, Including Assessed Tax of $628.37 million for the 12-month period ending 2022-05-31, per its 10-K filed 2022-07-28.
Discontinued › Income Statement › Revenue
us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax · last filed 2022-07-28
- Tilray Brands, Inc. revenue from contract with customer, including assessed tax for the quarter ending 2022-05-31 was $153.32M, a 7.80% increase year-over-year.
- Tilray Brands, Inc. revenue from contract with customer, including assessed tax for the quarter ending 2022-02-28 was $151.87M, a 216.26% increase year-over-year.
- Tilray Brands, Inc. revenue from contract with customer, including assessed tax for the quarter ending 2021-11-30 was $155.15M, a 174.32% increase year-over-year.
- Tilray Brands, Inc. revenue from contract with customer, including assessed tax for the quarter ending 2021-08-31 was $168.02M, a 226.85% increase year-over-year.
- Tilray Brands, Inc. revenue from contract with customer, including assessed tax for fiscal 2022 was $628.37M, a 22.47% increase from fiscal 2021.
- Tilray Brands, Inc. revenue from contract with customer, including assessed tax for fiscal 2021 was $513.09M.
- Tilray Brands, Inc. revenue from contract with customer, including assessed tax for fiscal 2020 was $210.48M.
- Tilray Brands, Inc. revenue from contract with customer, including assessed tax for fiscal 2020 was $405.33M.
| Period end | Revenue from Contract with Customer, Including Assessed Tax 3 month | Revenue from Contract with Customer, Including Assessed Tax 6 month | Revenue from Contract with Customer, Including Assessed Tax 9 month | Revenue from Contract with Customer, Including Assessed Tax 12 month |
|---|---|---|---|---|
| 2022-05-31 | $153.32M derived: 10-K 12 month − 10-Q 9 month · filed 2022-07-28 | $305.20M derived: sum of 2 quarters · filed 2022-07-28 | $460.35M derived: sum of 3 quarters · filed 2022-07-28 | $628.37M 10-K · filed 2022-07-28 |
| 2022-02-28 | $151.87M 10-Q · filed 2022-04-06 | $307.02M derived: sum of 2 quarters · filed 2022-04-06 | $475.05M 10-Q · filed 2022-04-06 | $617.28M derived: sum of 4 quarters · filed 2022-04-06 |
| 2021-11-30 | $155.15M 10-Q · filed 2022-01-10 | $323.18M 10-Q · filed 2022-01-10 | $465.41M derived: sum of 3 quarters · filed 2022-01-10 | |
| 2021-08-31 | $168.02M 10-Q · filed 2021-10-07 | $310.26M derived: sum of 2 quarters · filed 2021-10-07 | ||
| 2021-05-31 | $142.24M 10-K · filed 2021-07-28 | $513.09M 10-K · filed 2022-07-28 | ||
| 2021-03-31 | $48.02M 10-Q · filed 2021-05-10 | |||
| 2021-02-28 | $123.90M 10-Q · filed 2022-04-06 | $370.85M 10-Q · filed 2022-04-06 | ||
| 2020-12-31 | $56.56M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-19 | $210.48M 10-K · filed 2021-02-19 | ||
| 2020-12-30 | $56.56M 10-K · filed 2021-02-19 | |||
| 2020-11-30 | $129.46M 10-Q · filed 2022-01-10 | $246.95M 10-Q · filed 2022-01-10 | ||
| 2020-09-30 | $51.41M 10-K · filed 2021-02-19 | $153.92M 10-Q · filed 2020-11-09 | ||
| 2020-08-31 | $117.49M 10-Q · filed 2021-10-07 | |||
| 2020-06-30 | $50.41M 10-K · filed 2021-02-19 | $102.52M 10-Q · filed 2020-08-10 | ||
| 2020-05-31 | $113.54M 10-K · filed 2021-07-28 | $405.33M 10-K · filed 2022-07-28 | ||
| 2020-03-31 | $52.10M 10-Q · filed 2021-05-10 | |||
| 2020-02-29 | $107.74M 10-K · filed 2021-07-28 | |||
| 2019-12-31 | $46.94M 10-K · filed 2021-02-19 | $166.98M 10-K · filed 2021-02-19 | ||
| 2019-11-30 | $89.97M 10-K · filed 2021-07-28 | |||
| 2019-09-30 | $51.10M 10-K · filed 2021-02-19 | $120.04M 10-Q · filed 2020-11-09 | ||
| 2019-08-31 | $94.08M 10-K · filed 2021-07-28 | |||
| 2019-06-30 | $45.90M 10-K · filed 2021-02-19 | $68.94M 10-Q · filed 2020-08-10 | $84.47M derived: sum of 3 quarters · filed 2021-02-19 | $94.52M derived: sum of 4 quarters · filed 2021-02-19 |
| 2019-05-31 | $179.30M 10-K · filed 2021-07-28 | |||
| 2019-03-31 | $23.04M 10-K · filed 2021-02-19 | $38.57M derived: sum of 2 quarters · filed 2021-02-19 | $48.62M derived: sum of 3 quarters · filed 2021-02-19 | $58.36M derived: sum of 4 quarters · filed 2021-02-19 |
| 2018-12-31 | $15.53M 10-K · filed 2020-03-02 | $25.58M derived: sum of 2 quarters · filed 2020-03-02 | $35.32M derived: sum of 3 quarters · filed 2020-03-02 | $43.13M 10-K · filed 2021-02-19 |
| 2018-09-30 | $10.05M 10-K · filed 2020-03-02 | $19.79M derived: sum of 2 quarters · filed 2020-03-02 | $27.60M 10-Q · filed 2018-11-14 | $32.71M derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-06-30 | $9.74M 10-K · filed 2020-03-02 | $17.55M 10-Q · filed 2018-08-29 | $22.66M derived: sum of 3 quarters · filed 2020-03-02 | $28.07M derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-03-31 | $7.81M 10-K · filed 2020-03-02 | $12.92M derived: sum of 2 quarters · filed 2020-03-02 | $18.33M derived: sum of 3 quarters · filed 2020-03-02 | $23.32M derived: sum of 4 quarters · filed 2020-03-02 |
| 2017-12-31 | $5.11M 10-K · filed 2019-03-25 | $10.52M derived: sum of 2 quarters · filed 2019-03-25 | $15.51M derived: sum of 3 quarters · filed 2019-03-25 | $20.54M 10-K · filed 2020-03-02 |
| 2017-09-30 | $5.41M 10-K · filed 2019-03-25 | $10.40M derived: sum of 2 quarters · filed 2019-03-25 | $15.43M 10-Q · filed 2018-11-14 | |
| 2017-06-30 | $4.99M 10-K · filed 2019-03-25 | $10.02M 10-Q · filed 2018-08-29 | ||
| 2017-03-31 | $5.03M 10-K · filed 2019-03-25 | |||
| 2016-12-31 | $12.64M 10-K · filed 2019-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Canopy Growth Corp (CGC) | $0.395B | ||
| USANA HEALTH SCIENCES INC (USNA) | United States | $0.264B | -17.90 |
| Niagen Bioscience, Inc. (NAGE) | United States | $0.238B | 15.72 |
| FITLIFE BRANDS, INC. (FTLF) | United States | $0.087B | 16.59 |
| MANNATECH INC (MTEX) | United States | $0.014B | |
| NATURAL ALTERNATIVES INTERNATIONAL INC (NAII) | United States | $0.011B | -1.16 |
| Synergy CHC Corp. (SNYR) | United States | $0.001B | |
| Functional Brands Inc. (MEHA) | United States | $0.001B | |
| Cronos Group Inc. (CRON) | $1.223B | ||
| Definium Therapeutics, Inc. (DFTX) | United States | $4.931B | -17.87 |